Appearance
move to sidebar
hide
| Clinical data | |
|---|---|
| Trade names | Chlor-trimeton, Polaramine |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a682543 |
| Routes of administration | Oral, Intravenous |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Elimination half-life | 21 to 27 hours |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.042.779 |
| Chemical and physical data | |
| Formula | C16H19ClN2 |
| Molar mass | 274.79 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Dexchlorpheniramine (trade name Polaramine) is an antihistamine with anticholinergic properties used to treat allergic conditions such as hay fever or urticaria.[1][2] It is the pharmacologically active dextrorotatory isomer of chlorpheniramine.
It came into medical use in 1959 and was patented in 1962.[3]
Pharmacology
[edit source]Dexchlorpheniramine is an antihistamine, or an antagonist of the histamine H1 receptor. A study found that dexchlorpheniramine had a Ki value of 20 to 30 μM for the muscarinic acetylcholine receptors using rat brain tissue.[4]
References
[edit source]- ↑ Theunissen EL, Vermeeren A, Ramaekers JG (January 2006). "Repeated-dose effects of mequitazine, cetirizine and dexchlorpheniramine on driving and psychomotor performance". British Journal of Clinical Pharmacology. 61 (1): 79–86. doi:10.1111/j.1365-2125.2005.02524.x. PMC 1884990. PMID 16390354.
- ↑
- ↑ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 547. ISBN 9783527607495.
- ↑ Yamamura HI, Snyder SH (May 1974). "Muscarinic cholinergic binding in rat brain". Proceedings of the National Academy of Sciences of the United States of America. 71 (5): 1725–1729. Bibcode:1974PNAS...71.1725Y. doi:10.1073/pnas.71.5.1725. PMC 388311. PMID 4151898.